Skip to main content
PMC home page
Indian Journal of Otolaryngology and Head & Neck Surgery logoLink to Indian Journal of Otolaryngology and Head & Neck Surgery
. 2010 Jan 9;61(4):320–332. doi: 10.1007/s12070-009-0091-8

Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis

M Sudhakara Rao 1, D Dwarakanatha Reddy 2,✉, P S N Murthy 3
PMCID: PMC3450081  PMID: 23120659

Abstract

Rupatadine is a once-daily, non-sedating, selective and long-acting new drug with a strong antagonist activity towards both histamine H1 receptors and platelet-activating factor receptors. The use of rupatadine is indicated in adult and adolescent patients (>12 years of age) suffering from intermittent and persistent allergic rhinitis. In the treatment of these conditions, rupatadine is at least as effective as ebastine, cetirizine, loratadine and desloratadine. Avery good safety profile of rupatadine has been evidenced in various studies, including a long-term (1-year) safety study. Rupatadine does not present drug-drug interactions with azithromycin, fluoxetine and lorazepam, but should not be administered concomitantly with known CYP3A4 inhibitors.

Keywords: antihistamine, platelet-activating factor, rhinitis, rupatadine

Full Text

The Full Text of this article is available as a PDF (325.3 KB).

References

  • 1.Skoner D.P. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin. Inmunol. 2001;108(Suppl.):S2–S8. doi: 10.1067/mai.2001.115569. [DOI] [PubMed] [Google Scholar]
  • 2.Boulay M.E., Boulet L.P. The relationships between atopy, rhinitis and asthma: pathophysiological considerations. Curr. Opin. Allergy Clin. Inmunol. 2003;3:51–55. doi: 10.1097/00130832-200302000-00009. [DOI] [PubMed] [Google Scholar]
  • 3.Bousquet J., Cauwenberge P., Khaltaev N. Aria Workshop Group and World Health Organization. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001;108(Suppl.5):S147–S334. doi: 10.1067/mai.2001.118891. [DOI] [PubMed] [Google Scholar]
  • 4.Howarth P.H. Cellular basis for allergic rhinitis. Allergy. 1995;50(Suppl.23):6–10. doi: 10.1111/j.1398-9995.1995.tb02734.x. [DOI] [PubMed] [Google Scholar]
  • 5.Eiser N.M., Mills J., Snashall P.D., Guz A. The role of histamine receptors in asthma. Clin. Sci. 1981;60:363–370. doi: 10.1042/cs0600363. [DOI] [PubMed] [Google Scholar]
  • 6.Greaves M.W. Chronic idiopathic urticaria. Curr. Opin. Allergy Clin. Immunol. 2003;3:363–368. doi: 10.1097/00130832-200310000-00008. [DOI] [PubMed] [Google Scholar]
  • 7.Negro-Alvarez J.M., Miralles-López J.C. Chronic idiopathic urticaria treatment. Allergol. Immunopathol. 2001;29:129–132. doi: 10.1016/s0301-0546(01)79045-3. [DOI] [PubMed] [Google Scholar]
  • 8.O’Donnell B.F., Lawlor F., Simpson J., Morgan M., Greaves M.W. The impact of chronic urticaria on the quality of life. Br. J. Dermatol. 1997;136:197–201. doi: 10.1111/j.1365-2133.1997.tb14895.x. [DOI] [PubMed] [Google Scholar]
  • 9.Kozel M.M.A., Sabroe R.A. Chronic urticaria. Aetiology, management and current future treatment options. Drugs. 2004;64:2515–2536. doi: 10.2165/00003495-200464220-00003. [DOI] [PubMed] [Google Scholar]
  • 10.Albert D. H., Malo P. E., Tapang P., et al. The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J. Pharmacol.Exp. Ther. 1998;284:83–88. [PubMed] [Google Scholar]
  • 11.Albert D. H., Tapang P., Morgan D.W., et al. ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in Brown Norway rats. Inflam. Res. 1997;46(Suppl.2):S133–S134. doi: 10.1007/s000110050141. [DOI] [PubMed] [Google Scholar]
  • 12.Yamada Y., Yokota M. Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory and atherosclerotic diseases. Jpn. Circ. J. 1998;62:328–335. doi: 10.1253/jcj.62.328. [DOI] [PubMed] [Google Scholar]
  • 13.Evans T.W., Rogers D.F., Aursudkij B., Chung K.F., Barnes P.J. Inflammatory mediators involved in antigen-induced airway microvascular leakage in guinea pigs. Am. Rev. Respir. Dis. 1988;138:395–399. doi: 10.1164/ajrccm/138.2.395. [DOI] [PubMed] [Google Scholar]
  • 14.Labrakis-Lazanas K., Lazanas M., Koussissis M., Tournis S., Demopoulos J. Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airwais. Am. Rev. Respir. 1989;140:142–147. doi: 10.1164/ajrccm/140.1.142. [DOI] [PubMed] [Google Scholar]
  • 15.Shirasaki H., Asakura K. Detection of platelet-activating factor in nasal lavage fluid from patients with pollinosis and experimental animals with nasal allergy. Nippon Jibiinkoka Gakkai Kaiko. 1990;93:420–427. doi: 10.3950/jibiinkoka.93.420. [DOI] [PubMed] [Google Scholar]
  • 16.Sciberras D.G., Bolognese J.A., Goldemberg M.M., James I., Baber N.S. Platelet-activating factor induced inflammatory responses in the skin. Prostaglandins. 1988;35:833. doi: 10.1016/0090-6980(88)90230-4. [DOI] [Google Scholar]
  • 17.Snyder F. Metabolic processing of PAF. Clin. Rev Allergy. 1994;12:309–327. doi: 10.1007/BF02802298. [DOI] [PubMed] [Google Scholar]
  • 18.Prescott S.M., Zimmerman G.A., Mcintyre T.M. The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In: Snyder F., editor. Platelet-Activating Factor and Related Lipid Mediators. New York: Plenum Press; 1987. pp. 323–240. [Google Scholar]
  • 19.Juhlin L. Cetirizine in the treatment of chronic urticaria. Clin. Ther. 1991;13:81–86. [PubMed] [Google Scholar]
  • 20.Townley R.G., Okada C.H. Use of cetirizine to investigate non-H1 effects of second-generation antihistamines. Ann.Allergy. 1992;68:190–196. [PubMed] [Google Scholar]
  • 21.Eda R., Sigiyama H., Hopp R.J., Bewtra A.K., Townley R.J. Effect of loratadine on human eosinophil function in vitro. Ann.Allergy. 1993;71:373–378. [PubMed] [Google Scholar]
  • 22.Merlos M., Giral M., Balsa D., et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF) J. Pharmacol. Exp. Ther. 1997;280:114–121. [PubMed] [Google Scholar]
  • 23.J Uriach Y Compania S.A.:Rupatadine (INN) Fumarate. Clinical Investigator Brochure. April 2005.
  • 24.Izquierdo I., Nieto C., Ramis J., Cooper M., Dewland P., Forn J. Pharmacokinetic and dose linearity of rupatadine fumaratein healthy volunteers. Meth. Find. Exp. Clin. Pharmacol. 1997;19(Suppl.A):189. [Google Scholar]
  • 25.Solans A., Merlos M., Antonijoan R., et al. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin: a randomized, cross-over, multiple dose, open study. Allergy Clin. Immunol. Int. 2005;1:159. [Google Scholar]
  • 26.Wernicke J.F. Safety and side effect profile of fluoxetine. Expert Opin. Drug Saf. 2004;3:495–504. doi: 10.1517/14740338.3.5.495. [DOI] [PubMed] [Google Scholar]
  • 27.Queralt M., Brazis P., Merlos M., Mora F., Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-a release from dispersed canine skin mast cells and the human cell line HMC-1. Inflam. Res. 2000;49:355–360. doi: 10.1007/PL00000216. [DOI] [PubMed] [Google Scholar]
  • 28.Huther K. J., Rentfle G., Barrand N., Burke J. T., Kich-Weser J. Inhibitory activity of terfenadine on histamine-induced skin wheals in man. Eur. J. Clin. Pharmacol. 1977;12:195–199. doi: 10.1007/BF00609860. [DOI] [PubMed] [Google Scholar]
  • 29.DN B., PH C., MD R. The effects of astemizole on histamine-induced weal and flare. Eur. J. Clin. Pharmacol. 1983;25:547–551. doi: 10.1007/BF00542126. [DOI] [PubMed] [Google Scholar]
  • 30.Garcia — Gea C., Barbanoj M.J., Morte A., et al. Peripheral anti H1 and central nervous system activity of single increasing oral doses of rupatadin fumarate. Meth. Find. Exp. Clin. Pharmacol. 1997;19(Suppl.A):203. [Google Scholar]
  • 31.Queralt M., Merlos M., Giral M., Puigdemont A. Dual effect of rupatadine on enema induced by PAF and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Develop. Res. 1996;39:12–18. doi: 10.1002/(SICI)1098-2299(19960901)39:1<12::AID-DDR2>3.0.CO;2-N. [DOI] [Google Scholar]
  • 32.Merlos M, Balsa D, Giral M, Ferrando R, Garcia-Rafanell J, Forn J: Inhibition of rat peritoneal mast cell exocytosis by rupatadine fumarate: a study with different secretagogues. Rupatadine 2000 Expert Opin. Pharmacother. (2006) 7(14) Meth. Find. Exp. Clin. Pharmacol. (1997) 19(Suppl.A):148.
  • 33.Merlos M., Ferrando R., Giral M., Ramis I., Forn J. Effect of rupatadine in experimental conjuntivitis in guinea pigs: macroscopic evaluation of ocular lesions. J. Allergy Clin. Immunol. 2001;107(Suppl.2):S310. [Google Scholar]
  • 34.Queralt M., Brazís P., Merlos M., Puigdemont A. Inhibitory effects of rupatadine on mast cell histamine release and skin wheal development induced by Ascaris suum, in hypersensitive dogs. Drug Develop. Res. 1998;44:49–55. doi: 10.1002/(SICI)1098-2299(199806/07)44:2/3<49::AID-DDR1>3.0.CO;2-A. [DOI] [Google Scholar]
  • 35.Merlos M., Ramis I., Balsa D., Queralt M., Brazís P., Puigdemont A. Inhibitory effect of rupatadine on TNF-a release from human monocytes and mast cell line HMC-1. J. Allergy Clin. Immunol. 2000;105(Suppl.1):S62. doi: 10.1016/S0091-6749(00)90622-5. [DOI] [Google Scholar]
  • 36.Barrón S., Ramis I., Merlos M. Effect of rupatadine on lymphocytic cytokine production. Allergy Clin. Immunol. 2005;Suppl.1:427. [Google Scholar]
  • 37.Roumestan C., Henriquet C., Mathieu M., Bousquet J. Effects of rupatadine on inflammatory mediators and transcription factors: a comparison with desloratadine and levocetirizine. Allergy Clin. Immunol. Int. 2005;Suppl.1:450. [Google Scholar]
  • 38.Barrón S., Ramis I., García-Rafanell J., Merlos M. Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find. Clin. Pharmacol. 2005;27(Suppl.2):161. [Google Scholar]
  • 39.Merlos M, Balsa D, Giral M, García-Rafanell J, Forn J: Antiallergic properties of UR-12592, a dual antihistamine and PAF antagonist. Presented at The XV International Congress of Allergology and Clinical Immunology. Stockholm, Sweden (1994).
  • 40.Giral M., Balsa D., Ferrando R., Merlos M., García-Rafanell J., Forn J. CNS activity profile of rupatadine fumarate, a new dual receptor antagonist of platelet-activating factor(PAF) and histamine. Allergy. 1998;53(Suppl.):321. [Google Scholar]
  • 41.Barbanoj M.J., García — Gea C., Morte A., Izquierdo I., Pérez I., Jané F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 2004;50:311–321. doi: 10.1159/000080959. [DOI] [PubMed] [Google Scholar]
  • 42.Barbanoj M. J., García-Gea C., Antonijoan R., et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum. Psychopharmacol. 2006;21:13–26. doi: 10.1002/hup.741. [DOI] [PubMed] [Google Scholar]
  • 43.Vuurman E, Van Oers A, Van Leeuwen C, Muñoz G: Comparative effects of rupatadine, hydroxyzine and placebo on actual driving performance on healthy volunteers. J. Uriach y Compañía, S.A. Data on file.
  • 44.Ronsky E., Boggs P., Findlay S., et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 1995;96:139–147. doi: 10.1016/S0091-6749(95)70001-3. [DOI] [PubMed] [Google Scholar]
  • 45.Jobst S., Winjaart W., Schubert A., Venne H. Assessment of the efficacy and safety of three dose levels of cetirizine in children with perennial allergic rhinitis. Allergy. 1994;49:598–604. doi: 10.1111/j.1398-9995.1994.tb00125.x. [DOI] [PubMed] [Google Scholar]
  • 46.Izquierdo I., Paredes I., Lurigados C., Sospedra E., Cooper M., Thomas H. A dose ranging study of rupatadine fumarate in patients with seasonal allergic rhinitis. Allergy. 2005;55(Suppl.63):275. [Google Scholar]
  • 47.Izquierdo I., Merlos M., García-Rafanell J. A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Drug of Today. 2003;39(6):451–468. doi: 10.1358/dot.2003.39.6.799450. [DOI] [PubMed] [Google Scholar]
  • 48.Guadaño E.M., Serra-Batlles J., Meseguer J., et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59:766–771. doi: 10.1111/j.1398-9995.2004.00576.x. [DOI] [PubMed] [Google Scholar]
  • 49.Martínez-Cócera C., Molina M., Martí-Guadaño E., et al. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J. Invest. Allergol. Clin. Immunol. 2005;15:22–29. [PubMed] [Google Scholar]
  • 50.Saint Martin F., Dumur J. P., Pérez I., Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF andmH1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Invest. Allergol. Clin. Immunol. 2004;14:34–40. [PubMed] [Google Scholar]
  • 51.Clinical Study Report: a 4-week multicentre, double-blind, randomized, placebo and active treatment controlled, parallel-group trial to assess the efficacy and safety of rupatadine in the treatment of Seasonal Allergic Rhino-conjunctivitis (SAR). J. Uriach y Compañía, S.A. Data on file. This study reports that rupatadine is more efficacious than loratoadine.
  • 52.Stuebner P., Horak F., Zieglmayer R., et al. Effects of rupatadine versus placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann. Allergy Asthma Immunol. 2006;96:37–44. doi: 10.1016/S1081-1206(10)61038-1. [DOI] [PubMed] [Google Scholar]
  • 53.Maspero J, Fantin S, Bisbal C et al.:A12-week placebo-controlled study of rupatadine 10 mg once daily comparative with cetirizne 10 mg once daily, in the treatment of persistent allergic rhinitis. Presented at The XXV Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria (10–14 June 2006)Abstract 758.
  • 54.Izquierdo I, Valero A, García O, Pérez I, Mullol J, Van Cauwenberge P: Clinical efficacy of rupatadine in allergic rhinitis Ander ARIA criteria: pooled analysis. Allergy Clin. Immunol. Int. (2005).
  • 55.Arnaiz E, Zalupca L, Cristodoulo T et al.: Efficacy and safety of rupatadine 5, 10 and 20 mg once daily in the treatment of chronic idiopathi urticaria: a double-blind, randomized, placebo-controlled, dose finding trial. Allergy Clin. Immunol. Int. (2005)
  • 56.Gimenez-Arnau A, Ianosi S, Pérez I et al.: Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. J. Uriach y Compañía, S.A. Data on file. [DOI] [PubMed]
  • 57.Valero A, Rivas P, Castillo JA et al.: One year safety of rupatadine 10 mg in patients with allergic rhinitis. Presented at The XXV Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria (10–14 June 2006)Abstract 759. Long-term study reporting that rupatadine is a welltolerated antihistamine.
  • 58.Committee For Medicinal Products For Human Use: CHMP/EWP/2455/02. Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis (2005).
  • 59.Ich Topic E1A Note For Guidance: Population exposure: the extent of population exposure to assess clinical safety (1995).
  • 60.Giral M., Merlos M., Balsa D., Ferrando R., García-Rafanell J., FORN J. Effects of rupatadine on cardiovascular profile in rats and guinea pigs. Comparison with other nonsedating antihistamines. Allergy. 1997;52(Suppl.37):044. [Google Scholar]
  • 61.Ich E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs (2004).
  • 62.Donado E, García O, Pérez I et al.: Cardiac safety of rupatadine according to the new ICH guideline: A ‘thorough QT/QTc study’. Presented at The XXV Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria (10–14 June 2006)Abstract 760.

Articles from Indian Journal of Otolaryngology and Head & Neck Surgery are provided here courtesy of Springer

RESOURCES